{"title":"Prefectural Survey on Immune Checkpoint Inhibitor-Associated Myocarditis at the Start of the Basic Plan to Promote Cancer Control Programs - Phase 4.","authors":"Yuji Okura, Satoru Miura, Naohito Tanabe, Kazuyuki Ozaki, Takeshi Kashimura, Akira Kikuchi, Tatsuya Takenouchi, Hiroshi Tanaka, Yasuo Saijo, Takayuki Inomata","doi":"10.1253/circrep.CR-24-0171","DOIUrl":"10.1253/circrep.CR-24-0171","url":null,"abstract":"<p><strong>Background: </strong>In 2023, collaboration between cardiologists and oncologists was recommended as part of Japan's Basic Plan to Promote Disease Control Programs for both cancer and cardiovascular diseases. This study explores the extent of this collaboration in Niigata Prefecture.</p><p><strong>Methods and results: </strong>Self-administered questionnaires about immune checkpoint inhibitor-associated myocarditis (ICIAM) and anthracycline-related cardiomyopathy (ARCM) were distributed to all cardiologists and leading oncologists in hospitals across the Prefecture, of whom 124 cardiologists and 41 oncologists across 29 hospitals responded. Clinical experience with ICIAM was reported by 31.8% of cardiologists and 24.4% of leading oncologists, significantly lower than experience with ARCM (80.0% of cardiologists, P<0.001, and 58.5% of leading oncologists, P=0.009, respectively). Senior cardiologists reported less experience with ICIAM compared with their young counterparts (18.6% vs. 38.5%, P=0.018). Of the 20 hospitals providing immunotherapy, 12 (60%) reported \"no consultation\" between the cardiology and oncology departments, and only 5 hospitals (25%) had matching answers for consultation after ICIAM onset between these departments. Conversely, only 4 hospitals (20%) answered \"no consultation\", and 12 hospitals (60%) had matching answers, for interdepartmental consultation before or after ARCM onset.</p><p><strong>Conclusions: </strong>Compared with ARCM, cardiologists and oncologists had less experience, fewer organized measures in place, and increased interdepartmental collaboration vulnerability with ICIAM. Collaboration between cardiologists and oncologists should be promoted in hospitals.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"176-182"},"PeriodicalIF":0.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Developing a Collaborative Model for Cardiac Rehabilitation - Linking Hospitals and Local Fitness Centers for Older Adults With Cardiovascular Disease.","authors":"Takuya Ozeki, Akihiro Hirashiki, Kakeru Hashimoto, Ikue Ueda, Tatsuya Yoshida, Takahiro Kamihara, Manabu Kokubo, Shigeru Sakakibara, Masaki Wada, Yoshihisa Hirakawa, Hitoshi Kagaya, Susumu Suzuki, Mitsutaka Makino, Hidenori Arai, Atsuya Shimizu","doi":"10.1253/circrep.CR-24-0169","DOIUrl":"10.1253/circrep.CR-24-0169","url":null,"abstract":"<p><strong>Background: </strong>Cardiac rehabilitation (CR) is a comprehensive program designed to help cardiac patients reintegrate into social life. The maintenance phase (phase III) is typically conducted in hospitals or at local exercise facilities, depending on individual lifestyles. Effective collaboration between hospitals and local exercise facilities is essential for maintaining CR in older adults with cardiovascular disease (CVD), but several barriers hinder this linkage.</p><p><strong>Methods and results: </strong>Since 2022, the Aichi Health Plaza has maintained CR by developing a unique collaboration handbook (the <i>Cardiac Rehabilitation Exercise Facility Cooperation Medical Institutions</i> [CREpas] handbook). A collaboration system was established with the Department of Cardiology at the National Center for Geriatrics and Gerontology, facilitating seamless transitions through referrals after outpatient center-based CR. Partnerships included methods for information sharing, such as a collaboration diary, training records, occasional telephone calls and emails, and biannual information exchange meetings. A total of 18 collaboration patients was enrolled, and no severe adverse events occurred during exercise. However, 11 (61%) of the 18 patients discontinued the program for various reasons.</p><p><strong>Conclusions: </strong>Transferring CR from hospitals to fitness centers is crucial for older adults with CVD. While safety was ensured at fitness centers, program interruptions highlight the need for addressing barriers to continuity. Seamless healthcare transitions for older CVD patients remain a key challenge in the context of the heart failure pandemic and require further discussion.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"154-159"},"PeriodicalIF":0.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Myocardial T1 Mapping, Left Ventricular Parameters, and Cardiac Biomarkers in Wild-Type Transthyretin Amyloid Cardiomyopathy Before and After Tafamidis Treatment.","authors":"Yuki Ikegami, Toshiro Kitagawa, Yoshiharu Sada, Daiki Okamoto, Kotaro Hamamoto, Fuminari Tatsugami, Kazuo Awai, Yukiko Nakano","doi":"10.1253/circrep.CR-24-0170","DOIUrl":"10.1253/circrep.CR-24-0170","url":null,"abstract":"<p><strong>Background: </strong>To further elucidate the clinical implications of myocardial T1 mapping with cardiac magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy (ATTR-CM), we investigated the relationships of native myocardial T1 value (T1<sub>native</sub>) and extracellular volume fraction (ECV) with left ventricular (LV) parameters and cardiac biomarkers in ATTR-CM patients before and after tafamidis treatment.</p><p><strong>Methods and results: </strong>We studied wild-type ATTR-CM patients who underwent baseline CMR with LV cine and T1 mapping techniques. T1<sub>native</sub> and ECV were derived from averaged values of base-to-apex LV myocardium. Cardiac biomarkers, including high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), were measured at baseline. In a subset of the patients, follow-up CMR was performed and cardiac biomarkers were remeasured 1 year after initiation of tafamidis treatment. Both T1<sub>native</sub> (n=66) and ECV (n=50) positively correlated with LV end-diastolic volume index, LV mass index, Ln (hs-cTnT), and Ln (NT-proBNP). T1<sub>native</sub> correlated negatively with LV ejection fraction. Multivariate analysis showed that Ln (hs-cTnT) independently correlated with increased T1<sub>native</sub> (β=0.32; P=0.033). In the tafamidis follow-up group, changes in T1<sub>native</sub> (∆T1<sub>native</sub>) (n=30) and ECV (n=21) after treatment (follow-up-baseline values) negatively correlated with their baseline values. ∆T1<sub>native</sub> positively correlated with ∆NT-proBNP concentration (r=0.45; P=0.013).</p><p><strong>Conclusions: </strong>T1<sub>native</sub> and ECV are comprehensive indicators of LV characteristics in wild-type ATTR-CM patients and may provide imaging-based evidence of meaningful changes after tafamidis treatment.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"198-206"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Novel Missense Variant of <i>ZC3H12A</i> in Pulmonary Arterial Hypertension.","authors":"Ryotaro Asano, Makoto Okazawa, Tomohiko Ishibashi, Xin Ding, Keiko Ohta-Ogo, Kotaro Akaki, Saori Umeki-Mizushima, Akiko Yamagishi, Tadakatsu Inagaki, Ai Yaku, Shinya Fujisaki, Takatoyo Kiko, Kinta Hatakeyama, Osamu Takeuchi, Takeshi Ogo, Yoshikazu Nakaoka","doi":"10.1253/circrep.CR-25-0007","DOIUrl":"10.1253/circrep.CR-25-0007","url":null,"abstract":"<p><strong>Background: </strong>Because Regnase-1, encoded by <i>ZC3H12A</i>, suppresses the development of pulmonary arterial hypertension (PAH) by controlling pro-inflammatory cytokines, we aimed to identify <i>ZC3H12A</i> variants in patients with PAH.</p><p><strong>Methods and results: </strong>We analyzed whole-genome sequence data of patients with PAH to search for disease-associated <i>ZC3H12A</i> variants. The Regnase-1 p.D426G variant was identified in 2 patients, 1 of whom presented with prominent infiltration of inflammatory cells in the lung. The protein level of the variant was decreased in vitro.</p><p><strong>Conclusions: </strong>We identified a novel missense variant of <i>ZC3H12A</i> that is directly involved in regulating inflammation in patients with PAH.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"207-211"},"PeriodicalIF":0.0,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Role of Cardio-Oncology Rehabilitation in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.","authors":"Shohei Moriyama, Moe Kondo, Ryuichi Awamura, Michinari Hieda, Mitsuhiro Fukata","doi":"10.1253/circrep.CR-24-0161","DOIUrl":"10.1253/circrep.CR-24-0161","url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy often lead to severe sarcopenia and cachexia during treatment, making it difficult to maintain exercise tolerance. Consequently, \"cancer rehabilitation\" programs have been implemented to sustain and improve physical activity and motor function. Hematologic malignancies often involve the use of cardiotoxic drugs. Moreover, graft-vs.-host disease associated with allo-HSCT and the cytokine release syndrome in CAR-T therapy elevate the risk of cardiovascular complications. Thus, establishing \"cardio-oncology rehabilitation\" (CORE) is essential to support cancer patients and survivors. CORE is expected to enhance quality of life, improve cardiopulmonary function, reduce cancer and cardiac events recurrence, and prolong survival. Our institution conducts cardiopulmonary exercise testing before HSCT and CAR-T therapy, with exercise prescriptions based on heart rate at the anaerobic threshold and guidance on resistance exercises. This report discusses current trends in CORE for patients undergoing HSCT and CAR-T therapy, along with future challenges.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 2","pages":"59-65"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Usefulness of the LAVITA Telemonitoring System in Patients With Heart Failure - A Feasibility Study.","authors":"Masahiro Noguchi, Akihiro Nomura, Yasuaki Takeji, Masaya Shimojima, Shohei Yoshida, Teppei Kitano, Keisuke Ohtani, Hayato Tada, Shinichiro Takashima, Kenji Sakata, Masayuki Takamura, Soichiro Usui","doi":"10.1253/circrep.CR-24-0099","DOIUrl":"10.1253/circrep.CR-24-0099","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) hospitalization is increasing in Japan's aging population. Current guidelines recommend daily biometric monitoring for patients with HF to facilitate early clinical intervention. However, promoting patient self-management remains insufficient. Therefore, we assessed the usefulness of the LAVITA telemonitoring system, which automatically obtains and stores the biometric data of patients with HF via wireless devices.</p><p><strong>Methods and results: </strong>This prospective, single-arm, multicenter cohort study enrolled patients with HF. Patients were introduced to the LAVITA telemonitoring system and trained to measure body weight, blood pressure, pulse rate, oxygen saturation (SpO<sub>2</sub>), physical activity with activity trackers (AT), and electronic patient-reported outcomes (ePRO). The primary outcome was the measurement rate of each cetology at 9-12 weeks post-discharge. The secondary outcomes included the subgroup analyses by age, sex, and left ventricular function. Thirty patients continued to use the system at home. The measurement rates of patient data were as follows: body weight 92.4% (interquartile range [IQR] 83.3-97.8%); blood pressure 95.6% (IQR 84.8-98.5%); pulse rate 96.5% (IQR 86.5-98.8%); SpO<sub>2</sub> 93.1% (IQR 76.6-97.9%); AT 88.4% (IQR 31.3-98.5%); and ePRO 76.9% (IQR 26.4-95.9%). The subgroup analysis did not significantly differ.</p><p><strong>Conclusions: </strong>The LAVITA telemonitoring system had high measurement rates for the biometric data of patients with HF, including elderly patients. Hence, it can possibly improve patient self-management and facilitate early clinical intervention.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 2","pages":"106-112"},"PeriodicalIF":0.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Circulation reportsPub Date : 2025-01-25eCollection Date: 2025-02-10DOI: 10.1253/circrep.CR-24-0107
Haruka Matsuura, Tsukasa Kamakura, Koji Miyamoto, Kengo Kusano
{"title":"Utility of the Tissue Proximity Indication Feature in Predicting Reconnection of Pulmonary Vein Isolation During Pulsed-Field Ablation.","authors":"Haruka Matsuura, Tsukasa Kamakura, Koji Miyamoto, Kengo Kusano","doi":"10.1253/circrep.CR-24-0107","DOIUrl":"10.1253/circrep.CR-24-0107","url":null,"abstract":"","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 2","pages":"144-145"},"PeriodicalIF":0.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11808249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of High-Risk Pregnancy on Peripartum Left Ventricular Function.","authors":"Yasuyo Komoriya, Kazuo Komamura, Hiroshi Miyake, Hisashi Umeda, Koichi Kobayashi, Ryoji Ishiki, Hidenori Oguchi, Toyoaki Murohara, Mitsunori Iwase","doi":"10.1253/circrep.CR-24-0154","DOIUrl":"10.1253/circrep.CR-24-0154","url":null,"abstract":"<p><strong>Background: </strong>Predictors of the clinical characteristics of pregnant women at risk of peripartum cardiomyopathy (PPCM) remain unclear.</p><p><strong>Methods and results: </strong>We enrolled 450 cases of high-risk pregnancy with any risk factor from among ≥35 years of age, hypertensive disorders of pregnancy (HDP), multiple gestation, or other systemic or obstetric complications except for a history of cardiac disease. All the women underwent echocardiography and plasma B-type natriuretic peptide (BNP) measurement during the second/third trimester and the early/late postpartum period. Logistic regression analyses identified clinical factors associated with left ventricular (LV) dysfunction. The incidence of PPCM was 0.89%, which was higher than in previous reports. Early diastolic mitral annular velocity (e') was significantly negatively associated with the occurrence of PPCM, and the BNP level showed a significant positive association with the occurrence of PPCM. The percentages of cases of e' <7 cm/s, and BNP level ≥100 pg/mL were 25.3%, and 20.4%, respectively. Multivariate regression analysis revealed that HDP was independently associated with e'. A negative correlation between e' and BNP level was observed in HDP.</p><p><strong>Conclusions: </strong>High-risk pregnancy was associated with an increased incidence of PPCM. Measurement of BNP levels and echocardiographic assessment of LV diastolic function during pregnancy may be useful in predicting PPCM.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 2","pages":"122-130"},"PeriodicalIF":0.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Circulation reportsPub Date : 2025-01-22eCollection Date: 2025-02-10DOI: 10.1253/circrep.CR-24-0150
Daiki Hirayama, Susumu Manabe, Norihisa Yuge
{"title":"Impact of Transaortic Valve Flow Velocity on the Development of Systolic Heart Murmurs.","authors":"Daiki Hirayama, Susumu Manabe, Norihisa Yuge","doi":"10.1253/circrep.CR-24-0150","DOIUrl":"10.1253/circrep.CR-24-0150","url":null,"abstract":"<p><strong>Background: </strong>Although cardiac auscultation plays an essential role in detecting valvular heart diseases, false-positive rates due to innocent heart murmurs remain a concern because accelerated transaortic valve blood flow can be a major contributor to systolic heart murmurs. In this study we investigated the effect of transaortic valve flow velocity on the development of systolic heart murmurs.</p><p><strong>Methods and results: </strong>Cardiac auscultation was performed in 571 patients referred for echocardiography and systolic heart murmur was detected in 103 (18.0%). Maximum transaortic valve flow velocity was higher in patients with murmurs than in those without (2.02 vs. 1.34 m/s, P<0.001; area under the receiver operating characteristic curve, 0.82). A cutoff maximum transaortic flow velocity of 1.7 m/s predicted systolic heart murmurs (sensitivity, 65%; specificity, 88%). The incidence of heart murmur was associated with higher maximum transaortic valve flow velocity (<1.7 m/s, 7.3%; 1.7-2.5 m/s, 50.0%; >2.5 m/s, 73.5%). Multivariate analysis revealed the maximum transaortic valve flow velocity as an independent predictor of systolic heart murmurs (hazard ratio, 9.18; 95% confidence interval, 5.35-15.75; P<0.001).</p><p><strong>Conclusions: </strong>Accelerated transaortic valve flow velocity is an important determinant of systolic heart murmurs. Systolic heart murmurs can be heard before the transaortic valve flow velocity reaches the clinically significant aortic stenosis criterion, which can constitute a considerable number of innocent heart murmurs.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 2","pages":"139-142"},"PeriodicalIF":0.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}